The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook
The approval enables the company to directly sell health insurance plans to individuals and families while integrating its managed healthcare delivery model into retail offerings
The platform offers personalised recovery plans, AI-driven movement tracking, and access to certified physiotherapists for more than 250 conditions
Conceptualized as an aggregator platform it integrates existing programme systems through an API-based federated architecture
The company has also launched Elyara, a portfolio of products in regenerative medical aesthetics focused on non-invasive skin and hair restoration
AI-enabled technology platform delivers integrated pharmacovigilance solutions with measurable efficiency gains and enhanced compliance
Under the new policy, financial assistance has been increased to Rs 50 lakh per patient to improve treatment access
The ISG assessment highlights Indegene’s deep domain expertise, proprietary technology stack, and expanding use of AI and GenAI to drive more integrated, data-led commercial execution across the life sciences value chain
Enterprise-scale adoption in 2026 will be driven by domain-specific AI, compliance automation, and strong digital foundations across quality, manufacturing and regulatory workflows
Subscribe To Our Newsletter & Stay Updated
